Aflac (AFL) Set to Announce Earnings on Wednesday

Aflac (NYSE:AFL) is scheduled to be releasing its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect Aflac to post earnings of $1.58 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Aflac (NYSE:AFL) last announced its earnings results on Thursday, February 1st. The financial services provider reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.47 by ($0.22). Aflac had a net margin of 24.92% and a return on equity of 17.59%. The business had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $4.44 billion. During the same quarter last year, the firm earned $1.29 EPS. On average, analysts expect Aflac to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Aflac Trading Up 1.1 %

Shares of NYSE AFL opened at $84.54 on Tuesday. Aflac has a fifty-two week low of $64.10 and a fifty-two week high of $86.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.06 and a current ratio of 0.06. The company has a market cap of $48.64 billion, a price-to-earnings ratio of 10.91, a PEG ratio of 2.29 and a beta of 0.91. The business’s 50 day moving average price is $82.79 and its 200-day moving average price is $81.82.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AFL shares. Evercore ISI downgraded Aflac from an “in-line” rating to an “underperform” rating and lifted their target price for the stock from $76.00 to $78.00 in a research report on Thursday, January 4th. Keefe, Bruyette & Woods lifted their price objective on shares of Aflac from $83.00 to $87.00 and gave the company a “market perform” rating in a report on Wednesday, April 10th. StockNews.com downgraded shares of Aflac from a “hold” rating to a “sell” rating in a research note on Wednesday, April 10th. The Goldman Sachs Group increased their price objective on Aflac from $61.00 to $75.00 and gave the stock a “sell” rating in a research note on Tuesday, January 9th. Finally, Raymond James lifted their target price on Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Aflac has a consensus rating of “Hold” and a consensus price target of $82.15.

Insider Activity

In related news, Director Masatoshi Koide sold 30,493 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the completion of the sale, the director now directly owns 86,090 shares in the company, valued at approximately $6,879,451.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Thomas J. Kenny sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $84.62, for a total value of $423,100.00. Following the sale, the director now directly owns 17,920 shares in the company, valued at approximately $1,516,390.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Masatoshi Koide sold 30,493 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the transaction, the director now owns 86,090 shares of the company’s stock, valued at approximately $6,879,451.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,493 shares of company stock worth $3,765,706. 0.90% of the stock is currently owned by company insiders.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.